Analysis of functional results of surgical treatment of kidney cancer

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. The result of surgical treatment of kidney cancer (KC) is determined not only by cancer-specific survival, but also by impaired renal function, which may occur in the patient as a concomitant pathology or develop after surgery, especially afterf radical nephrectomy. Timely diagnosis and prevention of renal dysfunction progression in patients with KC is an urgent task of modern onconephrology.

Objective. This literature review analyzes the functional results of surgical treatment of KC.

Material and methods. A review of published scientific literature in the Pubmed, Elsevier, Springer, and Elibrary databases for 2018–2023was conducted.

Results. A review of the scientific literature showed that patients with KC often have concomitant chronic kidney disease. In addition, malignant kidney tumors themselves are associated with an increased risk of nephropathies.

Conclusion. The use of organ-sparing operations for KC makes it possible to preserve renal function to a greater extent at the initial (preoperative) level, prevent the development or progression of existing renal dysfunction and improve the functional outcomes of treatment and the quality of life of patients.

全文:

受限制的访问

作者简介

Sergey Popov

St. Petersburg St. Luke Clinical Hospital; S. M. Kirov Military Medical Academy

编辑信件的主要联系方式.
Email: doc.popov@gmail.com
ORCID iD: 0000-0003-2767-7153

Dr.Sci. (Med.), Professor, Chief Physician of St. Petersburg St. Luke Clinical Hospital, Head of the Center for Endoscopic Urology and New Technologies, Professor at the Department of Urology, S.M. Kirov Military Medical Academy, Head of the Department of Urology, St. Petersburg Medical and Social Institute

俄罗斯联邦, St. Petersburg; St. Petersburg

Ruslan Guseynov

St. Petersburg St. Luke Clinical Hospital; St. Petersburg State University

Email: rusfa@yandex.ru
ORCID iD: 0000-0001-9935-0243

Cand.Sci. (Med.), Deputy Chief Physician for Scientific Activities, St. Petersburg St. Luke State Clinical Hospital, Teaching Assistant at the Department of Hospital Surgery, St. Petersburg State University

俄罗斯联邦, St. Petersburg; St. Petersburg

Ashot Yesayan

St. Petersburg St. Luke Clinical Hospital

Email: essaian.ashot@gmail.com
ORCID iD: 0000-0002-7202-3151

Dr.Sci. (Med.), Professor, Head of the Department of Nephrology and Dialysis, Faculty of Postgraduate Education, Pavlov University, Chief External Expert in Nephrology of the Northwestern Federal District of the Russian Federation

俄罗斯联邦, St. Petersburg

Konstantin Sivak

St. Petersburg St. Luke Clinical Hospital; Smorodintsev Research Institute of Influenza

Email: doc.popov@gmail.com
ORCID iD: 0000-0003-4064-5033

Smorodintsev Research Institute of Influenza

俄罗斯联邦, St. Petersburg; St. Petersburg

Vitaly Perepelitsa

St. Petersburg St. Luke Clinical Hospital; St. Petersburg Medical and Social Institute

Email: perepelitsa_vit@mail.ru
ORCID iD: 0000-0002-7656-4473

Cand. Sci. (Med.), Urologist, St. Petersburg St. Luke Clinical Hospital

俄罗斯联邦, St. Petersburg; St. Petersburg

Anastasia Sadovnikova

St. Petersburg St. Luke Clinical Hospital

Email: stenia1407@mail.ru
ORCID iD: 0009-0004-9544-7944

Nephrologist, St. Petersburg St. Luke Clinical Hospital

俄罗斯联邦, St. Petersburg

Roman Grushevsky

St. Petersburg St. Luke Clinical Hospital

Email: doc.popov@gmail.com

Nephrologist, St. Petersburg St. Luke Clinical Hospital

俄罗斯联邦, St. Petersburg

Tatyana Lelyavina

St. Petersburg St. Luke Clinical Hospital; Almazov National Medical Research Center

Email: tatianalelyavina@mail.ru
ORCID iD: 0000-0002-1834-4982

Dr.Sci. (Med.), Leading Researcher at the Research Institute of Myocardial Microcirculation and Metabolism, Almazov National Medical Research Center

俄罗斯联邦, St. Petersburg; St. Petersburg

参考

  1. Capitanio U., Bensalah K., Bex A., et al. Epidemiology of Renal Cell Carcinoma. Eur. Urol. 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036.
  2. Tahbaz R., Schmid M., Merseburger A.S. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr. Opin. Urol. 2018;28(1):62–79. doi: 10.1097/MOU.0000000000000454.
  3. Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2022. 239 с. [The state of cancer care for the population of Russia in 2022. Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. M., 2022. 239 р. (In Russ.)].
  4. Harrison H., Thompson R.E., Lin Z., et al. Risk Prediction Models for Kidney Cancer: A Systematic Review. Eur. Urol. Focus. 2021;7(6):1380–90. doi: 10.1016/j.euf.2020.06.024.
  5. Муркамилов И.Т., Сабиров И.С., Фомин В.В. и др. Хроническая болезнь почек и злокачественные новообразования: современное состояние проблемы. Архивъ внутренней медицины. 2022;12(2):104–12. doi: 10.20514/2226-6704-2021-12-2-104-112. [Murkamilov I.T., Sabirov I.S., Fomin V.V., et al. Chronic kidney disease and malignant neoplasms: current state of the problem. Arch. Int. Med. 2022;12(2):104–12 (In Russ.)].
  6. Hu M., Wang Q., Liu B. et al. Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms. Front. Cell. Dev. Biol. 2022;10:868715. doi: 10.3389/fcell.2022.868715.
  7. Xie Y., Bowe B., Mokdad A.H., et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–81. doi: 10.1016/j.kint.2018.04.011.
  8. Lee M., Wang Q., Wanchoo R., et al. Chronic Kidney Disease in Cancer Survivors. Adv. Chron. Kidney Dis. 2021;28(5):469–76.e1. Doi: 10.1053/ j.ackd.2021.10.007.
  9. de Francisco A.L.M., Macía M., Alonso F., et al. Onco-Nephrology: Cancer, chemotherapy and kidney. Nefrol. (Engl Ed). 2019;39(5):473–81. English, Spanish. doi: 10.1016/j.nefro.2018.10.016.
  10. Zabell J., Demirjian S., Lane B.R., et al. Predictors of Long-Term Survival after Renal Cancer Surgery. J. Urol. 2018;199(2):384–92. Doi: 10.1016/ j.juro.2017.08.096.
  11. Есаян А.М., Аль-Шукри С.Х., Мосоян М.С. Почечно-клеточный рак и хроническая болезнь почек: внимание к отдаленным неонкологическим исходам. Нефрология. 2012;16(4):94–9. [Yesayan A.M., Al-Shukri S.H., Mosoyan M.S. Renal cell carcinoma and chronic kidney disease: attention to long-term non-oncological outcomes. Nephrol. 2012;16(4):94–9 (In Russ.)].
  12. Huang W.C., Donin N.M., Levey A.S., Campbell S.C. Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. J. Urol. 2020;203(3):475–85. doi: 10.1097/JU.0000000000000326.
  13. Кульченко Н.Г. Лечение локализованного рака почки. Южно-Российский онкологический журнал. 2020;1(1):69–75. doi: 10.37748/2687-0533-2020-1-1-6. [Kulchenko N.G. Treatment of localized kidney cancer. South Rus. J. Oncol. 2020;1(1):69–75 (In Russ.)].
  14. Okhawere K.E., Grauer R., Zuluaga L., et al. Operative and oncological outcomes of salvage robotic radical and partial nephrectomy: a multicenter experience. J. Robot. Surg. 2023;17(4):1579–85. doi: 10.1007/s11701-023-01538-6.
  15. DiBianco J.M., Gomella P.T., Ball M.W. Renal function after kidney surgery: “it’s tough to make predictions, especially about the future”. Ann. Transl. Med. 2019;7(Suppl. 3):S82. doi: 10.21037/atm.2019.04.01.
  16. Wood A.M., Benidir T., Campbell R.A., et al. Long-Term Renal Function Following Renal Cancer Surgery: Historical Perspectives, Current Status, and Future Considerations. Urol. Clin. North Am. 2023;50(2):239–59. doi: 10.1016/j.ucl.2023.01.004.
  17. Capibaribe D.M., Coelho M.O.S., Reis L.O. How to draw the line between partial and radical nephrectomy. Int. Braz. J. Urol. 2021;47(4):784–86. doi: 10.1590/S1677-5538.IBJU.2020.0149.1.
  18. Андреев С.С., Титяев И.И., Неймарк Б.А., Василенко А.А. Ранние признаки нарушения функции единственной почки после нефрэктомии по поводу рака почки. Уральский медицинский журнал. 2022;21(4):13–8. doi: 10.52420/2071-5943-2022-21-4-13-18. [Andreev S.S., Tityaev I.I., Neimark B.A., Vasilenko A.A. Early signs of dysfunction of a single kidney after nephrectomy for kidney cancer. Ural Med. J. 2022;21(4):13–8 (In Russ.)].
  19. Zabor E.C., Furberg H., Lee B., et al. Long-Term Renal Function Recovery following Radical Nephrectomy for Kidney Cancer: Results from a Multicenter Confirmatory Study. J. Urol. 2018;199(4):921–26. Doi: 10.1016/ j.juro.2017.10.027.
  20. Xiong S., Jiang M., Jiang Y., et al. Partial Nephrectomy Versus Radical Nephrectomy for Endophytic Renal Tumors: Comparison of Operative, Functional, and Oncological Outcomes by Propensity Score Matching Analysis. Front. Oncol. 2022;12:916018. doi: 10.3389/fonc.2022.916018.
  21. Klett D.E., Tsivian M., Packiam V.T., et al. Partial versus radical nephrectomy in clinical T2 renal masses. Int. J. Urol. 2021;28(11):1149–54. doi: 10.1111/iju.14664.
  22. Ahn T., Ellis R.J, White V.M., et al. Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population-based analysis. J. Surg. Oncol. 2018;117(7):1597–610. doi: 10.1002/jso.25037.
  23. Silagy A., Zabor E., Mano R., et al. Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. Can. Urol. Assoc. J. 2021;15(2):E103–9. doi: 10.5489/cuaj.6485.
  24. Roussel E., Laenen A., Bhindi B., et al. Predicting short- and long-term renal function following partial and radical nephrectomy. Urol. Oncol. 2023;41(2):110.e1–110.e6. doi: 10.1016/j.urolonc.2022.10.006.
  25. Zhou Z., Li Z., Ning K., et al. Long-term effect of acute ischemic injury on the kidney underwent clamped partial nephrectomy. Science. 2023;12;26(9):107610. doi: 10.1016/j.isci.2023.107610.
  26. Rosiello G., Capitanio U., Larcher A. Acute kidney injury after partial nephrectomy: transient or permanent kidney damage? Impact on long-term renal function. Ann. Transl. Med. 2019;7(Suppl. 8):S317. doi: 10.21037/atm.2019.09.156.
  27. Bravi C.A., Vertosick E., Benfante N., et al. Impact of acute kidney injury and its duration on long-term renal function after partial nephrectomy. Eur. Urol. 2019;76:398–403. 10.1016/j.eururo.2019.04.040.
  28. Волкова М.И., Ридин В.А., Черняев В.А. и др. Результаты резекции почки у больных опухолями почечной паренхимы с высоким нефрометрическим индексом. Экспериментальная и клиническая урология. 2019;(3):60–71. doi: 10.29188/2222-8543-2019-11-3-60-71. [Volkova M.I., Ridin V.A., Chernyaev V.A., et al. Results of kidney resection in patients with tumors of the renal parenchyma with a high nephrometric index. Exp. Clin. Urol. 2019;(3):60–71 (In Russ.)].
  29. Cacciamani G.E., Medina L.G., Gill T.S., et al. Impact of Renal Hilar Control on Outcomes of Robotic Partial Nephrectomy: Systematic Review and Cumulative Meta-analysis. Eur. Urol. Focus. 2019;5(4):619–35. doi: 10.1016/j.euf.2018.01.012.
  30. Мосоян М.С., Аль-Шукри С.Х., Семенов Д.Ю. и др. Селективная ишемия почечной паренхимы как альтернатива традиционному пережатию сосудистой ножки при резекции почки. Вестн. урологии. 2014;3:3–11. [Mosoyan M.S., Al-Shukri S.H., Semenov D.Yu., et al. Selective ischemia of the renal parenchyma as an alternative to traditional clamping of the vascular pedicle during kidney resection. J. Urol. 2014;3:3–11 (In Russ.)].
  31. Bravi C.A., Larcher A., Capitanio U., et al. Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORd 2 Project). Eur. Urol. Focus. 2021;7(2):390–96. doi: 10.1016/j.euf.2019.10.013.
  32. Santok G.D., Abdel Raheem A., Chang K.D., et al. Estimated glomerular filtration rate’s time to nadir after robot-assisted partial nephrectomy: Predictors and clinical significance on renal functional recovery. Int. J. Urol. 2018;25(7):660–67. doi: 10.1111/iju.13589.
  33. Zabell J., Isharwal S., Dong W., et al. Acute Kidney Injury after Partial Nephrectomy of Solitary Kidneys: Impact on Long-Term Stability of Renal Function. J. Urol. 2018;200(6):1295–301. doi: 10.1016/j.juro.2018.07.042.
  34. Suer E., Akpinar C., Izol V., et al. Predicting factors of acute kidney injury after partial nephrectomy and its impact on long-term renal function: A multicentre study of the Turkish Urooncology Association. Int. J. Clin. Pract. 2021;75(11):e14751. doi: 10.1111/ijcp.14751.
  35. Мосоян М., Румянцев А., Есаян А., Земченко А. Отдаленные результаты открытой, лапароскопической и робот-ассистированной резекции почки. Врач. 2917;11:79–82. [Mosoyan M., Rumyantsev A., Yesayan A., Zemchenko A. Long-term results of open, laparoscopic and robot-assisted kidney resection. Doctor. 2917;11:79–82 (In Russ.)].
  36. Дементьев И.О., Нюшко К.М., Карякин О.Б. и др. Роль биомаркеров острого повреждения почек в прогнозировании функциональных результатов хирургического лечения у больных локализованным раком почки. Исследования и практика в медицине. 2021;8(3):97–107. doi: 10.17709/2410-1893-2021-8-3-9. [Dementyev I.O., Nyushko K.M., Karyakin O.B., et al. The role of biomarkers of acute kidney injury in predicting the functional results of surgical treatment in patients with localized kidney cancer. Res. Pract. Med. 2021;8(3):97–107 (In Russ.)].
  37. Тарасенко А.И., Россоловский А.Н., Березинец О.Л. и др. Клиническое значение цистатина С и TGF-??????1 в оценке почечной функции при хирургическом лечении почечно-клеточного рака. Саратовский научно-медицинский журнал. 2020;16(3):786–92. [Tarasenko A.I., Rossolovsky A.N., Berezinets O.L., et al. Clinical significance of cystatin C and TGF-??????1 in the assessment of renal function during surgical treatment of renal cell carcinoma. Saratov Sci. Med. J. 2020;16(3):786–92 (In Russ.)].
  38. Димитриади С.Н., Франциянц Е.М., Ушакова Н.Д. и др. Биомаркеры в диагностике острого повреждения почек после органосохраняющего хирургического лечения локализованного рака почки. Мед. вестник Юга России. 2018;9(3):77–83. doi: 10.21886/2219-8075-2018-9-3-77-83. [Dimitriadi S.N., Frantsiantsets E.M., Ushakova N.D. et al. Biomarkers in the diagnosis of acute kidney injury after organ-conserving surgical treatment of localized kidney cancer. Medical Bulletin of the South of Russia. 2018;9(3):77-83 (In Russ.)].
  39. Мосоян М.С., Аль-Шукри С.Х., Есаян А.М. и др. NGAL-ранний биомаркер острого повреждения почек после резекции почки и нефрэктомии. Нефрология. 2013;17(2):55–9. [Mosoyan M.S., Al-Shukri S.H., Yesa- yan A.M., et al. NGAL is an early biomarker of acute kidney injury after partial nephrectomy and nephrectomy. Nephrol. 2013;17(2):55–9 (In Russ.)].
  40. Allinovi M., Sessa F., Villa G., et al. Novel Biomarkers for Early Detection of Acute Kidney Injury and Prediction of Long-Term Kidney Function Decline after Partial Nephrectomy. Biomed. 2023;11(4):1046. doi: 10.3390/biomedicines11041046.
  41. Wu J., Suk-Ouichai C., Dong W., et al. Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery. BJU Int. 2018;121(1):93–100. doi: 10.1111/bju.13994.
  42. Suk-Ouichai C., Tanaka H., Wang Y., et al. Renal Cancer Surgery in Patients without Preexisting Chronic Kidney Disease-Is There a Survival Benefit for Partial Nephrectomy? J. Urol. 2019;201(6):1088–96. doi: 10.1097/JU.0000000000000060.
  43. Bhindi B., Lohse C.M., Schulte P.J., et al. Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. Eur. Urol. 2019;75(5):766–72. doi: 10.1016/j.eururo.2018.11.021.
  44. Flammia R.S., Tufano A., Proietti F., et al. Renal surgery for kidney cancer: is preoperative proteinuria a predictor of functional and survival outcomes after surgery? A systematic review of the literature. Minerva Urol. Nephrol. 2022;74(3):255–64. doi: 10.23736/S2724-6051.21.04308-1.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##